Mergers & AcquisitionsMedium•5 November 2026•
1 min read
ANI Pharmaceuticals to Acquire Swedish Biotech Egetis for $560 Million
Key Facts
1ANI Pharmaceuticals announced a recommended public offer to acquire the entirety of Swedish biotech Egetis Therapeutics.
2The proposed acquisition deal is valued at approximately $560 million.
3The acquisition aims to expand the scope and scale of ANI's rare disease business.
ANI Pharmaceuticals announced a recommended public offer to acquire the entirety of Swedish biotech Egetis Therapeutics. The proposed acquisition deal is valued at approximately $560 million, according to Seeking Alpha. The acquisition aims to expand the scope and scale of ANI's rare disease business.
The strategic deal is designed to bolster ANI's presence in the rare disease treatment market and follows a recent agreement by Egetis to sell a priority review voucher. In related economic context, the Swedish central bank reached an interest rate decision on November 4, 2026, raising the rate to 2% from its previous level of 1.75%.